npj Vaccines (Jul 2022)

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

  • Sarah Kehr,
  • Philipp Berg,
  • Susanne Müller,
  • Sarah A. Fiedler,
  • Britta Meyer,
  • Gabriele Ruppert-Seipp,
  • Cornelia Witzenhausen,
  • Marc E. Wolf,
  • Hans H. Henkes,
  • Doris Oberle,
  • Brigitte Keller-Stanislawski,
  • Markus B. Funk

DOI
https://doi.org/10.1038/s41541-022-00491-z
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 4

Abstract

Read online

Abstract We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissions. Patient outcomes ranged from good recovery (13 patients, 29.6%) to moderate disability (11 patients, 25.0%) and severe disability or vegetative state (6 patients, 13.6%). Fatal outcomes were reported in 14 patients (31.8%).